Clinithink Wins Two Alconics 2019 Awards in San Francisco

Clinithink’s CLiX AI solution won two prestigious awards at the Alconics 2019 Awards held on 24 September in the Golden Ballroom of the Palace Hotel in San Francisco. Clinithink was presented with their winners’ trophies in two categories: ‘Best Application of AI in Healthcare’ and ‘Best Innovation in NLP’ (Natural Language Processing).

The world renowned AIconics Awards take place as the annual AI Summit commences, and they celebrate the best in artificial intelligence worldwide – recognising the outstanding achievements derived from harnessing breakthrough innovation.

For their award entries Clinithink outlined how CLiX delivers the deepest, fastest and most accurate analysis of unstructured patient data currently possible thanks to their ground-breaking clinical natural language processing ability. This enriched insight into the real narrative of the patient story within the electronic medical record opens up an entirely new healthcare landscape. By informing treatment decisions, diagnosing rare disease, by finding many more potential candidates (in less time) for clinical trials, and by protecting healthcare spending through reducing claims denials and avoidance, CLiX AI is changing patient care for everyone, both now and into the future.

CLiX is AI that is changing rare disease diagnosis to save lives.

In a collaboration with Rady Children’s Institute for Genomic Medicine (RCIGM) CLiX helped diagnose rare genetic disease in a world record breaking 19 hours. Thanks to this study our AI is now opening the door to the increased use of genome sequencing as a first-line diagnostic test for babies with rare genetic disorders. Dr Stephen Kingsmore, President and CEO of RCIGM: “Some people call this artificial intelligence, we call it augmented intelligence”.

CLiX is AI that is improving every patient’s access to potentially life changing clinical trials.

Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH) spent three years manually reviewing the medical records of over 2000 patients to identify just 30 potentially eligible candidates for a clinical trial. With CLiX ENRICH on board, NUTH were able to process the electronic medical records of 270,000 patients in less than 24 hours, providing a shortlist of 100 potentially eligible patients. Professor Yan Yiannakou, Director of the Phase III Unit for NUTH: “This is a genuinely intelligent system which is not dependent on coding – it actually reads the health record, producing eligibility lists which are always accurate.”

Dr Chris Tackaberry, CEO of Clinithink, said of the win: “It was just as well we had both Glenn Keet and Nathan Skorick attending the AIconics as it was incredible to receive two awards. We are immensely proud as we feel these awards just reiterate how our AI solutions are making a huge difference in the real world and driving an evolution in the development of healthcare services across the globe.”

The full list of AIconics 2019 winners can be found at

https://aibusiness.com/AIconics-awards-san-francisco-2019-winners-announced/


About Clinithink
Clinithink’s platform delivers the deepest, fastest and most accurate analysis of unstructured data across patient populations currently possible. This analysis provides medical professionals with the knowledge they need to quickly and accurately diagnose conditions and plan the most effective treatments. It enables our healthcare partners to provide optimal care to patients that is swiftly reimbursed, protecting their ability to deliver care to the people who need it most. And it can also fast forward drug development; ensuring protocols are optimized, patients matched and sites identified in a fraction of the time of manual processing – helping our life science associates get the treatments patients need to market faster. For further information visit clinithink.com

For more information contact marketing@clinithink.com

ABOUT THE AICONICS AWARDS:
Beginning in 2016, The AIconics provides innovators from around the globe with the platform to showcase themselves to their peers as well as millions of enterprise end-users. These prestigious global Awards create the ultimate showcase for the best and brightest people, projects and transformational innovations. With many new and exciting award categories now open for entries globally, the AIconics acknowledges the advances in technologies and disciplines being made, as we explore and push at the very definition of what can be accomplished by AI.

HEALTHeLINK Selects Clinithink and Stella Technology to support Their Analysis of HIE Data

HEALTHeLINK, the innovative Buffalo-based HIE, announces a groundbreaking collaborative partnership with two new technology providers.

 

August 20, 2019 – Buffalo, NY: Clinithink and Stella Technology’s solutions are to be put to task sifting through HEALTHeLINK’s HIE data to identify patients at-risk for non-alcoholic fatty liver disease (NAFLD). The resulting data will be compared, contrasted and ultimately combined, enabling HEALTHeLINK to identify exciting new ways of offering advanced analytics to physicians – exactly where and when those analytics are needed – for better, and more efficient, patient care.

 

As the regional health information organization for Western New York, HEALTHeLINK has been working for over 10 years to connect hospitals, laboratories, radiology practices and participating provider organizations to exchange clinical information.

 

Dan Porreca, executive director of HEALTHeLINK explained “Leveraging and accurately analyzing HIE data for the benefit of patients has been a consistent focus for us. We are always looking for innovative ways to build on our current capabilities to help our patients and physicians avoid gaps in care, find and treat undiagnosed diseases, and ultimately improve the quality (and lower the cost) of health care.”

 

Clinithink, a supplier of artificial intelligence and CNLP solutions, were chosen by HEALTHeLINK for their ability to harvest the information-rich unstructured clinical narrative of the electronic medical record (found within the typed or dictated patient stories recorded by physicians and nurses such as progress notes, operative reports, discharge summaries, radiology reports and referral letters).

 

Clinithink’s ENRICH platform reads all these documents at a rate of over one million per hour, encoding all the clinical concepts within them using post-coordinated SNOMED Clinical Terminology, and filtering the data output for the targeted therapeutic area (in this case those patients that meet the criteria for being at-risk for NAFLD).

 

As Clinithink’s AI/CNLP is advanced enough to understand negation in all its forms, understand the subtle differences between patient information and family history information, and understand severity levels and temporality, it is also able to eliminate false positives, making data more robust and therefore ultimately more able to improve patient care.

 

Stella Technology, a solution provider with deep expertise in clinical data and information exchange, was chosen by HEALTHeLINK for their ability to quickly and efficiently identify the patients with certain conditions within hundreds of structured database fields.

 

By using multi-step search criteria the Stella Prism platform, which was designed with flexibility and scalability at its core, enables search across numerous non-uniform health records from dozens of different sites and source systems. Following a “no data left behind” strategy, Prism allows healthcare organizations to find key insights from their complete data set within seconds (as opposed to the hours this search can take with more traditional analytics solutions).

 

Lalo Valdez, CEO of Stella, said “HEALTHeLINK is a great test bed for us because they have been so successful in establishing a connected infrastructure that has gathered 10 years of clinical reports from numerous hospitals and practices, adding up to many terabytes of rich clinical data. We very much look forward to helping find and analyze data for this study, which is exactly what Prism was designed to do.”

 

Glenn Keet, general manager of Clinithink, added “We are grateful to Dan Porecca and his team at HEALTHeLINK for including Clinithink in this exciting analysis opportunity, and we very much look forward to helping further define the future of HIE analytics alongside one of the most important HIEs in the world.”

For further information on Clinithink’s partnership with HEALTHeLINK please contact Glenn Keet

 

About HEALTHeLINK:

HEALTHeLINK is a collaboration among hospitals, physicians, health plans and other health care providers in the eight counties of western New York State to securely exchange clinical information to improve the quality of care, enhance patient safety and mitigate health care costs. HEALTHeLINK is a Qualified Entity of the Statewide Health Information Network for New York (SHIN-NY), which enables providers to access their patients’ data from across the state. HEALTHeLINK is also a founding member of the Strategic Health Information Exchange Collaborative (SHIEC), the national trade association of health information exchanges. Providers and patients can visit wnyhealthelink.com or @HEALTHeLINK on both Facebook and Twitter for more information.

 

About Clinithink:

Clinithink’s platform delivers the deepest, fastest and most accurate analysis of unstructured data across patient populations currently possible. This analysis provides medical professionals with the knowledge they need to quickly and accurately diagnose conditions and plan the most effective treatments. It enables our healthcare partners to provide optimal care to patients that is swiftly reimbursed, protecting their ability to deliver care to the people who need it most. And it can also fast forward drug development; ensuring protocols are optimized, patients matched and sites identified in a fraction of the time of manual processing – helping our life science associates get the treatments patients need to market faster. For further information visit www.clinithink.com

 

About Stella Technology:

In an increasingly vast and complex world of Health Information, Stella Technology’s team and solutions enable healthcare organizations to harness the power of their data to deliver more efficient and effective healthcare services. With accurate and high quality data as a foundational tenet of its advanced big data analytics capabilities, the Stella Prism platform unifies data silos to reveal powerful insights – clinical, administrative, operational – that are difficult to uncover with traditional analytics solutions. For more information, please visit stellatechnology.com or contact us at info@stellatechnology.com.

Worcestershire Health and Care NHS Trust Partners with Clinithink

Gaining bright new insights for Mental Health and Community thanks to CLiX ENRICH

 

Clinithink’s CLiX ENRICH solution is now being used by the Worcestershire Health and Care NHS Trust, a Global Digital Exemplar Trust (GDE) internationally recognised for delivering improvements in the quality of care through the world-class use of digital technologies and information.

 

The Worcestershire Health and Care NHS Trust is the main provider of community, children’s and mental health services across the Worcestershire area, employing over 3,500 staff, and recording around 26,000 patient contacts every week, and the Trust’s health team includes paediatricians, mental health nurses and other allied health professionals.

 

David Brown, IT Director at Worcestershire was the driving force behind the Trust’s successful GDE funding application and the recent partnership with Clinithink. David said “Clinithink‘s CLiX ENRICH is delivering real gold dust for us. It’s unique because it works from a clinicians’ perspective, using SNOMED coding to query the unstructured clinical narrative that makes up the majority of our patients’ clinical record. This approach allows us to search and display crucial clinical content in a format that the team can use as part of their clinical practice and decision making process, ensuring the very best outcomes for our patients. Working with Clinithink will deliver tangible benefits for the entire team – reducing clinical risk and administrative burden, increasing productivity, providing support to our clinical research programme, and enabling us to deliver the right care at the right time to the right patient”.

 

Clinithink‘s patented clinical natural language processing (CNLP) platform uses market-leading AI technology to accurately ‘read’ and interpret up to two million clinical documents an hour, automating the review of clinical notes, mining unstructured clinical narrative, and connecting clinicians with the complete patient journey in a way that has not been possible previously. But CLiX ENRICH’s potential to change the way that the NHS can understand and treat patients is enormous too, with improved business intelligence and reporting tools, predictive population analytics, risk stratification to support care pathways, and disease diagnostic support potential all being additional benefits.

 

Chris Tackaberry, Clinithink‘s CEO, said “We are delighted to be partnering with Worcestershire, to help optimise clinical, financial and research outcomes for the Trust with our AI/CNLP, and thereby helping them deliver world-class patient services”.

 

As a Global Digital Exemplar Trust, Worcestershire is committed to sharing their learning and experience through the creation of blueprints that enable other trusts to follow in their footsteps as quickly and effectively as possible. And there is no doubt that Clinithink very much look forward to collaborating in this knowledge sharing process too – working alongside the NHS to expand the amount of patient data available and to develop approaches to clinical data utilisation across the UK.

 

The way ahead is bright for every one of the UK’s GDEs as they embrace and adopt digital technology, but for the Worcestershire Health and Care NHS Trust and Clinithink, a partnership built on collaboration, trust and shared insight looks set to take great leaps along the NHS Five Year Forward journey.

 

For further information, contact Anne Quirk at Clinithink, or for media enquiries please contact Sarah Roberts/Leonie Onslow at Vane Percy PR on +44 (0)1737 821890.

Clinithink and Newcastle Upon Tyne Hospitals NHS Foundation Trust Shortlisted for Prestigious HSJ Award

Clinithink and Newcastle Upon Tyne Hospitals NHS Foundation Trust Shortlisted for Prestigious HSJ Award
 

  • Clinithink helps supercharge clinical trial patient recruitment at Newcastle Hospitals.
  • Clinithink’s AI solution, CliX ENRICH, processed over a quarter of a million patient records in hours.
  • Additional time saved is focused on increasing patient interaction.

     

    Clinithink has been shortlisted for the Connecting Services and Information Award at this year’s HSJ Awards, for their joint submission with Newcastle Upon Tyne Hospitals NHS foundation Trust.

     

    The submission was based on a partnership that saw Clinithink’s CLiX ENRICH solution successfully used by the Trust’s clinical research staff to transform the way patients, who are potentially eligible to participate in clinical trials, are initially identified. Traditionally this task is done manually and is very labour intensive, taking up valuable clinical research staff time which could be better spent talking to potentially eligible patients to explain the trial, better enabling them to decide if they want
    to participate.

     

    According to the NIHR’s own league table the Newcastle upon Tyne Hospitals NHS Foundation Trust’s clinical research centre is currently one of the top performing clinical research sites in the NHS for patient recruitment. But, despite being an established and high-profile clinical research institution, the Trust’s team had been seeking a more efficient patient recruitment model to support their clinical research function. The cost of recruitment continues to increase. A report by Cutting Edge Information reported that, between 2008 and 2011, the cost of recruitment per patient increased 88% in the UK. This is coupled with the cost of delays. More than three-quarters of all clinical trials experience delays, and with the daily bill for this being somewhere between US$600,000 and US$8m, the need for a more reliable and efficient solution is pressing.

     

    Prior to the use of CLiX ENRICH, the research team at Newcastle Hospitals had spent three years manually reviewing over 2000 patients, identifying 30 potentially eligible candidates for one trial during that time. Using Clinithink’s CLiX ENRICH solution the same team was able to process the records of 270,000 patients and identify people who were potentially highly eligible in less than 24 hours. This produced a shortlist of 100 patients in a fraction of the previous time.

     

    By utilising Clinithink’s ENRICH platform, valuable time has been released to enable research staff to focus on patient interaction and, in turn, improve patient access to clinical research, with its associated benefits.

     

    As a result of the Clinithink partnership, patients not previously identified by the research teams have been offered a chance to participate, resulting in a marked increase in patient access to clinical trials. By saving clinical research staff time in laborious pre-screening, use of the solution improves ROI on the R&D spend for the Trust.

     

    Professor Julia Newton, Deputy Medical Director of Newcastle upon Tyne Hospitals NHS foundation Trust said: “Working with Clinithink has changed how we deliver commercial work. We have topped the NIHR league tables for research for seven consecutive years now, we are proud of how we deliver to time and target, and we are always looking for ways to work better and more efficiently. Clinithink represents such innovation for us.”

     

    As a result of the success of this project the Newcastle team is looking to work with more NHS Trusts in the North East to expand patient access to clinical research still further with ENRICH. On an even wider scale, the NHS has announced its intention to replicate the model of Newcastle’s Phase 3 unit across five other regions in the UK.

     

    The capability of Clinithink’s ENRICH platform is not confined to clinical trials. The software can also be used to stratify patients based on their phenotype, thereby identifying which patients may benefit from genetic testing for rare disease. Combining the insights derived from the unstructured data, with the ever-increasing amount of biomarker information available, will allow ENRICH’s end users to better understand the phenotypic differences between cohorts of otherwise similar patients, enabling a greater understanding of disease progression and response to treatment.

     

    Chris Tackaberry, CEO of Clinithink, said of the news “We are exceptionally proud to make the shortlist for the Connecting Services and Information Award at this year’s HSJ Awards. Our work with Newcastle Hospitals has been truly exciting from the start, and to be recognised in this way for the impact our solution has made for the clinical team and their patients is terrific testimony to the hard work of all those involved on both sides of the collaboration. We await further news with great excitement!”

    The full list of nominees for the 2019 HSJ awards (partnered by GRI) can be found on https://awards.hsj.co.uk/2019-shortlist.

     

    Winners will be selected ahead of the 2019 HSJ awards ceremony, which is due to be held at the Battersea Evolution Centre in London on November 6th 2019.

     

    About Clinithink:

    Clinithink’s platform delivers the deepest, fastest and most accurate analysis currently possible of unstructured clinical data across patient populations. When used in revenue cycle, our analyses provide HIM professionals with the knowledge they need to quickly and accurately validate clinical documentation. It enables our partners to provide swift analysis for gaps in documentation to speed reimbursement and drive revenue back to their client’s bottom lines. For further information visit www.clinithink.com

     

    NOTES TO EDITORS

    For more information contact Sarah Roberts / Leonie Onslow, Vane Percy & Roberts, (T) +44 (0) 1737 821890, sarah@vanepercy.com

     

    ABOUT THE HSJ AWARDS

    The most coveted accolade in UK healthcare, the HSJ awards is the largest annual benchmarking and recognition programme for the health sector. Over the last 39 years the awards have been celebrating healthcare excellence through huge political, technological and financial challenges within the sector. Through a rigorous, fair and transparent judging process the awards produce a roll call of the best organisations, teams and people in the NHS and the wider health sector.

     

    ABOUT HSJ

    Health Services Journal is the only title to cover all aspects of publicly funded healthcare, providing news, analysis, best practise information from some of the most powerful and respected figures in health. The HSJ audience is formed of healthcare leaders from both clinical and non-clinical backgrounds and both public and private sectors.

    HSJ is published by Wilmington PLC, a company dedicated to providing information and training to professional business markets. Their publications across the Health, Risk and Compliance, Finance, Legal and Insight sectors are united by one common aim- to turn knowledge into advantage. Wilmington PLC enables professionals to enhance performance and innovation by providing high quality, relevant and reliable information, education and knowledge.

  • TrustHCS Partners with Clinithink to Add Artificial Intelligence to Their Revenue Cycle Offerings

    TrustHCS Partners with Clinithink to Add Artificial Intelligence to Their Revenue Cycle Offerings

     

    August 20, 2019 – Today sees the launch of a strategic new revenue cycle partnership. Powered by Clinithink’s ENRICH platform and TrustHCS’ renowned reputation in clinical documentation improvement (CDI) and health information management (HIM), the combined offering enables TrustHCS to significantly reduce the costs associated with 2nd line CDI review and denial appeals by using advanced AI and Clinical Natural Language Processing (CNLP).

     

    The current rise in clinical denials is creating a demand for better technology and expertise to handle the surging resource cost and accounts receivables impact. Until now, models of computer-aided coding and CDI have been unable to bridge this gap, but ENRICH, Clinithink’s AI/CNLP platform, accurately reads and understands deep clinical concepts that traditional NLPs have been unable to attribute meaning to.

     

    “After reviewing a number of platforms ENRICH was the first that could capture the deep clinical meaning critical to support high cost DRGs, but still avoid frustrating false positives. False positives drive up costs for us by creating rabbit holes that our CDI teams then have to chase. This new approach will allow us to ensure our client’s documentation supports the claim on both the front and the back end,” explains Cathy Brownfield, COO of TrustHCS.

     

    TrustHCS CEO Torrey Barnhouse adds “The addition of this innovative technology supports our continued evolution and growth as industry leaders. Healthcare organizations are struggling to recruit and retain HIM / Revenue Integrity leadership and expertise. With CLiX we are able to bridge that gap for them and quickly deliver results on an unprecedented scale and pace, reducing costs and driving revenue back to our clients.”

     

    “We are thrilled to be partnering with TrustHCS, a world leader in the CDI and HIM space” said Chris Tackaberry, CEO of Clinithink. “Our R&D teams have spent over 10 years developing an AI platform that is comprehensive enough to identify granular clinical concepts that can really change workflow for companies like Trust HCS, enabling more robust documentation that can reduce cost within the healthcare revenue cycle for the long term”.

     

    About TrustHCS:

    TrustHCS partners with healthcare organizations to provide quality staffing and advisory services that improve financial strength. Our middle-revenue cycle management solution advances the reliability, integrity and performance of our clients’ financial health. Our purpose is to help clinicians, HIM, revenue cycle and clinical documentation improvement leaders gain visibility, increase insight and strengthen the economic outcome of every patient encounter. Learn more about TrustHCS http://www.trusthcs.com

     

    About Clinithink:

    Clinithink’s platform delivers the deepest, fastest and most accurate analysis currently possible of unstructured clinical data across patient populations. When used in revenue cycle, our analyses provide HIM professionals with the knowledge they need to quickly and accurately validate clinical documentation. It enables our partners to provide swift analysis for gaps in documentation to speed reimbursement and drive revenue back to their client’s bottom lines. For further information visit www.clinithink.com

    Healthix Data and Clinithink AI – A Blueprint for Insight

    Clinithink and Healthix proudly announce an innovative partnership that harnesses the combined benefits of state-of-the-art artificial intelligence technology and massive health data to advance care for millions in New York City and Long Island

     

    August 14, 2019 – New York. Clinithink and Healthix – the largest public health information exchange (HIE) in the U.S. – are partnering on a program designed to leverage Healthix clinical data to facilitate assessment of pre-trial feasibility, ensuring the validity of protocol design. The effectiveness of the collaboration will improve population health in New York City and Long Island by eventually making cutting-edge treatments available to patients.

     

    With health data of over 17 million individuals, Healthix spans a comprehensive range of organizations, from large hospital systems and health plans to small community health centers and physician practices. Over one thousand organizations, across more than 7,000 facilities, are connected through Healthix, contributing a rich clinical data set that is updated with each patient encounter. Clinithink’s artificial intelligence and clinical natural language processing (AI/CNLP) platform will run queries on this HIE data to generate insights that can be used to improve patient wellbeing, both now and in the future.

     

    Providing a key element of the diagnostic pipeline was Clinithink’s patented clinical natural language processing platform, CLiX ENRICH. This ground-breaking solution quickly combs through a patient’s electronic medical record to 1) automatically extract all of the clinical information that has been documented about that patient and 2) compare this information to the many thousands of phenotypes and synonyms which are critical to the diagnosis of thousands of rare diseases. CLiX ENRICH can perform both of these tasks in a fraction of the time it would take a highly skilled physician – potentially saving lives in critical care situations.

     

    “We are constantly looking for ways to deliver enhanced value to our patients and healthcare community. Our partnership with Clinithink uniquely positions us to support an important industry need by driving innovation and supporting efficiencies in the design and implementation of clinical trials – all while remaining compliant with New York’s privacy policy guidelines,” said Todd M. Rogow, President and CEO of Healthix.

     

    While some health systems have already experienced moderate success in achieving these insights, the key difference for Healthix is that they connect multiple health systems in various settings, making them a valuable partner.

     

    Clinithink CEO Chris Tackaberry said “We are delighted to be partnering with Healthix to unlock the clinical data for such a diverse urban population with challenging healthcare needs. We are confident our tools can help improve clinical outcomes, as well as promote efficiency and reduce the healthcare costs associated with clinical trials and treatment protocols.”

     

    “We are incredibly excited that Healthix is becoming our latest AI/CNLP partner. Their large and growing HIE catchment area is projected to serve 20 million people before long, and the insights we can facilitate will therefore be even more impactful to the health and wellbeing of patients. Additionally, the expert technical staff at Healthix have expedited implementation and made access to clinical narrative simple and straightforward. We look forward to this being the blueprint for our future HIE partners,” added Glenn Keet, General Manager, Healthcare Solutions for Clinithink.

     

    About Clinithink:
    Clinithink’s platform delivers the deepest, fastest and most accurate analysis of unstructured data across patient populations currently possible. This analysis provides medical professionals with the knowledge they need to quickly and accurately diagnose conditions and plan the most effective treatments. It enables our healthcare partners to provide optimal care to patients that is swiftly reimbursed, protecting their ability to deliver care to the people who need it most. And it can also fast forward drug development; ensuring protocols are optimized, patients matched and sites identified in a fraction of the time of manual processing – helping our life science associates get the treatments patients need to market faster. For further information visit www.clinithink.com

     

    About Healthix:

    Healthix is the largest public Health Information Exchange (HIE) in the nation, bringing together over 1,100 healthcare organizations at thousands of locations across New York City and Long Island. Healthix provides secure access to clinical data of more than 17 million patients, for treatment, care coordination and quality improvement. Data available through Healthix includes a broad range of clinical information electronically delivered with each patient encounter from across New York State, 24/7 in real-time. Visit www.healthix.org

     

    To find out more, schedule an SHIEC 2019 meeting with glenn.keet@clinithink.com
    Visit www.clinithink.com
    Or email sarah@vanepercy.com for press enquiries

    British company, Clinithink, part of a collaboration helping to diagnose rare disease in record time

    GWR |logo

     
     
     
     
     
     

    A study published in Science Translational Medicine documents the role played by Clinithink’s patented clinical natural language processing platform in delivering genetic diagnoses to neonatal and pediatric intensive care physicians in record breaking time

     

    A new study, published today in Science Translational Medicine, details the pioneering work undertaken by a collaboration led by Stephen Kingsmore, MD, DSc, President and CEO of Rady Children’s Institute for Genomic Medicine (RGIGM). The team, which includes British company Clinithink, utilized a machine learning process and clinical natural language processing to diagnose rare genetic diseases in record time. This revolutionary method is providing speedy answers to physicians caring for infants in intensive care and opens the door to increased use of genome sequencing as a first-line diagnostic test for babies with rare genetic disorders.

     

    There are between 5000 and 8000 rare diseases affecting around 400 million people worldwide. The diagnosis of rare disease is a significant challenge as many physicians may have never encountered the symptoms before. As a result it can take, on average, 4.8 years for an accurate diagnosis of a rare disease to be made, with patients seeing an average of 7.3 physicians on this diagnostic odyssey. In February 2018 the same team achieved a GUINNESS WORLD RECORDS™ title for the Fastest genetic diagnosis, successfully reducing diagnosis time to just 19 hours. This is particularly significant as delays in diagnosis can lead to inappropriate management and disease progression, with misdiagnosis leading to additional interventions later deemed to be inappropriate given the underlying disorder.

     

    Providing a key element of the diagnostic pipeline was Clinithink’s patented clinical natural language processing platform, CLiX ENRICH. This ground-breaking solution quickly combs through a patient’s electronic medical record to 1) automatically extract all of the clinical information that has been documented about that patient and 2) compare this information to the many thousands of phenotypes and synonyms which are critical to the diagnosis of thousands of rare diseases. CLiX ENRICH can perform both of these tasks in a fraction of the time it would take a highly skilled physician – potentially saving lives in critical care situations.

     

    Dr Richard Gain, senior clinical terminologist at Clinithink and one of the authors on the Science Translational Medicine paper said: “The team at Clinithink thrive on the knowledge that we are crossing new frontiers within the research community in the diagnosis and management of rare diseases. The fact that the results of this study have been published in one of the most prominent scientific journals further certifies the incredibly exciting value of our technology. Most importantly, it is very humbling to know that the results of our work can go towards helping save the lives of critically ill children. It is prospects such as these – the chance to make a real difference – that drives everyone at Clinithink to continue innovating and honing our software”.

     

    Stephen Kingsmore said of the technology: “Some people call this artificial intelligence, we call it augmented intelligence. Patient care will always begin and end with the doctor and by harnessing the power of technology, we can quickly and accurately determine the root cause of genetic diseases. We rapidly provide this critical information to intensive care physicians so that they can focus on personalizing care for babies who are struggling to survive.”

     

    This important work represents the first time that rare diseases have been diagnosed using a supervised machine-learning system to analyse and interpret genetic disease testing results.

     

    Eric Topol, MD, Professor of Molecular Medicine at Scripps Research and author of the new book Deep Medicine said: “This is truly pioneering work by the RCIGM team – saving the lives of very sick newborn babies by using AI to rapidly and accurately analyse their whole genome sequence”.

     

    Dr Calum Yacoubian, Partner Success Lead, Life Sciences at Clinithink added: “The goal for the future is to scale this solution up for use in the clinical setting to expand access to life-changing genomic medicine. By reducing the time spent on less critical manual data review, we believe CLiX has the potential to augment the capabilities of the highly-trained human experts who work in this field, thereby offering life changing diagnostics, research and treatments to a breadth of patients that would not otherwise be possible”.

     

    FOR MEDIA INFORMATION: Sarah Roberts, (T) +44 (0) 1737 821890; (E) sarah@vanepercy.com

    Northwell Health Adopts Clinithink Technology to Accelerate Patient Identification for Clinical Trials

    Clinithink’s CLiX is now implemented and showing significant improvement in identifying candidates for clinical trials and research at one of the largest health systems in the US.

     

    Northwell Health is far more than a health system. A phenomenal centre of talent and excellence the organization cares for a service area of eight million people, across 23 hospitals and more than 700 outpatient locations. Northwell has 68,000 employees, including more than 30,000 physicians and nurses operating across a huge range of specialties.

     

    Northwell is also the home of The Feinstein Institute for Medical Research – a collaboration of creative thinkers who share a singular focus of advancing science to prevent disease and cure patients. Northwell’s overarching focus is on changing healthcare – not just by discovering the latest medical and scientific advancements, or by training the doctors of tomorrow, but by adopting innovative new software like CLiX to reinvent their approach to clinical research.

     

    Serving one of the most diverse patient populations in the US, Northwell Health has been quick to recognise that the adoption of AI and NLP technologies like CLiX could reinvent the clinical trial feasibility model – enabling the rapid identification of potential patients for clinical trial that had simply been missed before.

     

    And CLiX is now providing the deepest, fastest and most accurate analysis of unstructured patient data ever seen at Northwell – successfully identifying candidates for clinical trials in hours not months.

     

    In a proof of concept study of COPD at Northwell the total patient cohort considered was 939,378 patients and there were 3.3 million associated documents for review. CLiX assessed these patients against 22 individual criteria in just 30 hours – a fraction of the time it would have taken previously – producing an impressive 88 patients to review, all of whom were highly relevant to the trial.

     

    Elaine Brennan, Managing Director of Pharma Ventures at Northwell Health, said:  “What is really exciting about working with CLiX ENRICH is that it allows us to mine a much richer data set and identify potential patients across our entire network, not just the specific location where the study is being conducted.  Leveraging tools to support the patient identification and enrollment process is part of Northwell’s strategic goals to make clinical trials an option for patients and to make Northwell a premier destination for clinical trials.”

     

    What’s more, CLiX ENRICH has been easy to adopt at Northwell Health. The software effortlessly drills down to a granular level, that has only previously been possible by manual review, thereby dramatically speeding up the decision making process for the reviewer. In addition, as ENRICHed Lists focus pre-screening on those patients most likely to qualify for the clinical trial, Northwell has found that they have eliminated the ‘data noise’ they often experienced previously.

     

    Sarah Beeby, EVP, GM Life Sciences for Clinithink said:  “Northwell Health is a superb addition to Clinithink’s network. The strategic alliance between ourselves and Northwell recognises that narrative clinical data is a huge untapped asset for health systems around the world, and the fact that our technology enables Northwell to really leverage the breadth and depth of their immensely diverse patient population to rapidly identify potential patients for trial is a fact we are very proud of indeed.”

     

    For further information on Clinithink’s work with Northwell, or on what CLiX ENRICH software can do for your clinical trials, please contact marc.horowitz@clinithink.com

     

    About Clinithink 

    Clinithink’s platform delivers the deepest, fastest and most accurate analysis of unstructured data across patient populations currently possible. This analysis provides medical professionals with the knowledge they need to quickly and accurately diagnose conditions and plan the most effective treatments. It enables our healthcare partners to provide optimal care to patients that is swiftly reimbursed, protecting their ability to deliver care to the people who need it most.  And it can also fast forward drug development; ensuring protocols are optimized, patients matched and sites identified in a fraction of the time of manual processing – helping our life science associates get the treatments patients need to market faster. For further information visit clinithink.com

     

    About Northwell Health

    Northwell Health is New York State’s largest health care provider and private employer, with 23 hospitals, more than 700 outpatient facilities and more than 13,600 affiliated physicians. Northwell cares for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from Northwell’s communities. Northwell’s 68,000 employees – 16,000-plus nurses and 4,000 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. They are making breakthroughs in medicine at the Feinstein Institute for Medical Research. They are training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and at the Hofstra Northwell School of Graduate Nursing and Physician Assistant Studies. For further information visit Northwell.edu.

     

    – Ends –

     

    FOR MEDIA INFORMATION: Sarah Roberts, Vane Percy & Roberts, (T) +44 (0) 1737 821890; (E) sarah@vanepercy.com

    Newcastle Hospitals Improve Patient Recruitment with CLiX Software

    Following the successful conclusion of a pilot study, Clinithink’s CLiX software is now being used by the Newcastle upon Tyne Hospitals NHS Foundation Trust – one of the UK’s leading clinical research centres – to improve patient recruitment in their clinical trials.

    A strong, collaborative relationship has been established between Clinithink and the Newcastle Hospitals and, as CLiX has made Newcastle a more attractive clinical research site thanks to its improved patient recruitment capabilities, Newcastle is now looking to expand its use of Clinithink’s CLiX software into its non-commercial trial space too.

    Professor Julia Newton, Deputy Medical Director of Newcastle upon Tyne Hospitals said: “Working with Clinithink has changed how we deliver commercial work.  We have topped the NIHR league tables for research for seven consecutive years now, we are proud of how we deliver to time and target, and we are always looking for ways to work better and more efficiently. Clinithink represents such innovation for us.”

    Challenge & Solution

    Just like the rest of the clinical trials industry Newcastle had, in the past, suffered from recruitment challenges. The institution knew all too well that more than three-quarters of all clinical trials experience delay, with the daily bill for this delay being somewhere between $600,000 and $8m. Awareness of this, coupled with a desire to increase its commercial research activity, drove Newcastle to seek out a solution that would identify the appropriate patients for clinical trial recruitment more effectively.

    And Clinithink’s patented CLiX natural language processing (NLP) platform is that solution. It uses market-leading artificial intelligence (AI) technology to accurately ‘read’ and interpret up to two million clinical documents an hour, automating the review of a hospital’s clinical notes and connecting physicians and patients with suitable clinical trials.

    CLiX has also been proven to dramatically reduce the time and investment currently required to find and enrol patients into clinical trials. By quickly and efficiently processing existing unstructured patient data, sites are able to identify eligible subjects against trial-specific inclusion and exclusion criteria up to 20 times faster than by reviewing patient data manually.

    Prior to the use of CLiX ENRICH, the Newcastle research team had spent three years manually reviewing over 2000 patients, identifying 30 potentially eligible candidates during that time. But with CLiX ENRICH on board the team was able to process the records of 270,000 patients in less than 24 hours providing a shortlist of 100 potentially eligible patients in a fraction of the previous time.

    What’s more, this success has led not only to Clinithink’s software being embedded into Newcastle’s data warehouse but also into Newcastle’s recently completed Phase III Trial Unit.

    Professor Yan Yiannakou, Director of the Phase III Unit for the Newcastle Hospitals, said:  “This is a genuinely intelligent system which is not dependent on coding – it actually reads the health record, producing eligibility lists which are always accurate.  Our innovative P3 Clinical Research Unit is open for business and using Clinithink software because we know it works.”

    Next Steps

    So what’s next for Clinithink and Newcastle? The partners are looking to work with more NHS Trusts in and around Newcastle to expand the amount of patient data available and to further increase the number of potentially suitable patients identified for clinical trials. On an even wider scale, the NHS has announced its intention to replicate the model of Newcastle’s Phase 3 unit (with CLiX as an inherent part of that model) across five other regional trusts across the UK.

    Sarah Beeby, EVP, GM Life Sciences, Clinithink said: “We are extremely proud to be working with such a dynamic Trust and the collaboration between Clinithink and Newcastle continues to inspire and excite us. We very much look forward to the next steps in our mission to deliver patient insights for everyone.”

    For further information, visit http://www.clinithink.com

    Or email sarah@vanepercy.com for press enquiries

    Clinithink secures growth-equity investment to fuel growth

    Leading healthcare technology investors partner with Clinithink to unlock the potential of unstructured data to inform treatment decisions, identify candidates for clinical trials, and ensure appropriate reimbursement

     

    Clinithink, which offers healthcare and life sciences organizations powerful clinical data insights through its patented CLiX natural language processing (NLP) platform, has secured a growth-equity investment from TT Capital Partners (TTCP) and the MSD Global Health Innovation Fund (GHI) to expand its global footprint and continue to broaden its service offering.

     

    Clinithink CEO, Dr Chris Tackaberry said: “We are delighted to have been able to close this latest round of funding with TTCP and MSD GHI. Not only because it enables us to expedite our growth but, strategically, we now have two further partners whose business is all about innovation.”

     

    Narrative clinical patient data is a valuable asset in healthcare that has historically been inaccessible due to its lack of structure and the reliance on structured data and key word searches to interpret and understand this information. Clinithink’s CLiX technology uses market-leading artificial intelligence (AI) technology to accurately ‘read’ and interpret up to two million clinical documents an hour, impacting patient care across the healthcare continuum:

     

    • Precision medicine: Evidence suggests that phenotype is at least as important as genotype in diagnosis and the development of new treatments. Clinithink compares a patient’s extracted phenotype with over 12,000 phenotypes and over 15,000 synonyms describing the characteristics of thousands of rare diseases. Recently, Clinithink was part of a collaboration which achieved a GUINNESS WORLD RECORDS™ title for the fastest genetic diagnosis. The project successfully compressed the time needed to diagnose rare genetic disorders in newborns through DNA sequencing and phenotype analysis to 19.5 hours in a seamless end-to-end process. Clinithink participated in this exciting project with Rady Children’s Institute of Genomic Medicine (RCIGM), San Diego, California and its partners. This work also received a RARE Champion of Hope award from Global Genes® recognizing the contribution to rare disease diagnosis.
    • Patient matching for clinical trials and Real World Evidence (RWE) studies: An estimated 85% of all clinical trials will experience delays, with 94% being delayed by over a month. The financial impact can be massive, costing between $600,000 – $8 million every day. Many delays are caused because sites struggle to find and recruit patients. Clinithink automates the review of a hospital’s clinical notes and connects physicians and patients with clinical trials. Clinithink also helps leading biopharma and contract research organizations (CROs) with site selection and protocol optimization in order to accelerate drug development and get promising new therapies to patients by leveraging its solution to support real world data analysis.
    • Revenue cycle management (RCM): RCM is estimated to be a $90 billion market by 2022, representing the growing importance of capabilities that help optimize the healthcare system. Clinithink provides revenue cycle management capabilities to help hospitals and health systems review clinical documents to verify the appropriateness of diagnostic tests and treatments, while ensuring appropriate reimbursement.

     

    “Clinithink has a proven track record of turning data and information into actionable insight for its biopharma and healthcare provider customers,” said Conor Green, Partner at TT Capital Partners. “We look forward to collaborating with Clinithink’s world-class team as they continue to improve the lives of patients around the world.”

     

    “The ability to capture meaningful information from narrative clinical data across the healthcare spectrum is critical to driving innovation.” added Prem Tumkosit, Investment Principal at MSD Global Health Innovation Fund LLC, “We believe these capabilities have the potential to make a major contribution to changing the way healthcare is delivered.”

     

     

    About Clinithink

    Clinithink: Every patient, precisely

     

    Clinithink’s platform delivers the deepest, fastest and most accurate analysis of unstructured data across patient populations currently possible. This analysis provides medical professionals with the knowledge they need to quickly and accurately diagnose conditions and plan the most effective treatments. Which enables our healthcare partners to provide optimal care to patients that is swiftly reimbursed, protecting their ability to deliver care to the people who need it most. This analysis can also fast forward drug development; ensuring protocols are optimized, patients matched and sites identified in a fraction of the time of manual processing. This helps our life sciences associates get the treatments patients need to market faster.

     

    For more, visit http://www.clinithink.com

     

    About TT Capital Partners

    TT Capital Partners (TTCP) is the principal investing arm of the TripleTree platform, a healthcare merchant bank. TTCP collaborates with healthcare technology and services companies that have the potential to become market leaders.  Leveraging the insights garnered from a unique knowledge-based platform, TTCP has invested in some of the most innovative, high-growth businesses in healthcare. For more, visit www.ttcapitalpartners.com.

     

    About MSD Global Health Innovation Fund

    MSD Global Health Innovation Fund (GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy.  This investment strategy connects innovative companies with complementary technologies to develop integrated healthcare solutions. With a vision that data will be the currency in healthcare, GHI invests broadly in digital health.  GHI invests in platform companies with proven technologies or business models where MSD’s expertise and perspectives can accelerate revenue growth and enhance value creation.  For more, visit www.msdghifund.com

     

    Clinithink receives RARE Champion of Hope award for their ‘notable efforts’ in rare disease

    Clinithink has been selected to receive the RARE Champion of Hope – Collaborations in Science and Technology award at the 7th Annual RARE Patient Advocacy Summit on October 4th in Irvine, California.

     

    Over 200 individuals and organizations worldwide were nominated by their peers for a RARE Champion of Hope award for their notable efforts in rare disease advocacy, teen advocacy, science, medical care and treatment and collaborations.

     

    Along with their collaborators Rady Children’s Institute for Genomic Medicine and Alexion Pharmaceuticals, Clinithink was selected to receive the award because of the work which resulted in the successful compression of the time needed to diagnose rare genetic disorders in newborns through DNA sequencing to 19.5 hours.

     

    Clinithink’s CLiX solution has been shown to dramatically accelerate the diagnosis of rare disease. This was evidenced in the Rady-Alexion-Clinithink collaboration, for which the RARE Champion of Hope has been awarded, where Clinithink’s NLP solution was used for two key activities in the process:

    1. quickly combing through electronic medical records to extract crucial phenotype information
    2. comparing the extracted phenotype with over 12,000 phenotypes (plus an additional 15,000 synonyms) describing the characteristics of thousands of rare diseases.

     

    The Clinithink solution can perform both of these tasks in seconds compared to the hours or days it would take a highly skilled specialist physician to do.

     

    The diagnosis of rare disease is incredibly challenging and, if left undiagnosed these conditions are very expensive to manage and, often, life limiting. Genomics data has held great promise and, increasingly, evidence is suggesting that phenotype is at least as important as genotype in diagnosis and the development of new treatments. However, in order to be able to unlock the true value of such data AI tools, such as Clinithink’s patented CLiX Natural language processing (NLP) solution is essential.

     

    Sarah Beeby SVP, Life Sciences said: “Our work with Rady and Alexion has enabled us to evidence the value of our technology and, more importantly, be involved in projects that can help save the lives of those with rare diseases.

     

    “Narrative data is a valuable asset in healthcare but is largely inaccessible due to its lack of structure as existing technologies rely on structured data or key word searches. Our CLiX technology can ‘read’ thousands of clinical documents an hour and extract the information they contain. This has significant benefit in the clinical setting and is also very powerful for clinical trials as it can optimize the development process along the entire continuum.”

     

    Clinithink CEO, Dr Chris Tackaberry said: “We are absolutely delighted to be recognised together with our collaborators in the RARE Champion of Hope awards and very much look forward to meeting colleagues and peers involved in this exciting space at the RARE Patient Advocacy Summit in October.”

     

    http://www.clinithink.com

     

     

    Sarah Beeby joins Clinithink to champion its life sciences business

    Sarah Beeby has joined Clinithink as Senior Vice President of Life Sciences where she will be responsible for introducing new technology, in particular AI, to Lifescience projects.

    Sarah has over two decades of experience in the global life sciences space and brings a wealth of experience in life sciences having worked in a range of diverse roles. Sarah also has a wide range of operational, therapeutic and regulatory expertise with a focus on collaborative working opportunities to enhance delivery and patient experience. Sarah’s experience as a management team member at exec and board level has covered investment, strategy and operational efficiency and delivery of products and services.

     

    Prior to joining Clinithink Sarah was MD of Synexus and, utilised technology and collaborative working relationships to enhance delivery, profitability and the patient experience in research. She was also pivotal in negotiating a contract between Synexus and the Northumbria Healthcare NHS Foundation Trust. Together they established the North East Clinical Research Centre at Hexham General Hospital; a particular exciting partnership as it was the first of its kind between a private company and the NHS.

    Discussing the new role Sarah said: “We hear a lot about the potential of technology and how disruptive technology can bring about a host of benefits. Often, however, there is a disconnect between what is possible and what the market needs. I am really excited to join Clinithink as they are at the forefront of what is possible. Recently our software helped achieve a GUINNESS WORLD RECORDS title in partnership with the Rady Institute for Genomic Medicine for the ‘Fastest genetic diagnosis’ by successfully compressing the time needed to diagnose rare genetic disorders in newborns through DNA sequencing. Not only did this exciting project prove the value of our technology, the humbling reality is that this work can help save the lives of children with rare diseases. That really isn’t a bad day at the office.”

    Clinithink’s patented CLiX natural language processing (NLP) solution was needed for two key activities in the process: quickly combing through electronic medical records to extract crucial phenotype information to then compare with over 12,000 phenotypes (plus an additional 15,000 synonyms) describing the characteristics of thousands of rare diseases. The solution can perform both of these tasks in seconds compared to the hours or days it would take a highly skilled specialist physician to do.

    Narrative data is a valuable asset in healthcare but is largely inaccessible due to its lack of structure as existing technologies rely on structured data or key word searches. CLiX can ‘read’ thousands of clinical documents an hour and extract the information they contain. This has significant benefit, as shown with the Rady collaboration, in the clinical setting and is also very powerful for clinical trials as it can optimize the development process along the entire continuum – site selection, protocol optimization and enrolment. In simple terms our software can automate the bulk of pre-screening and site feasibility which is still undertaken manually. By targeting very specific patient inclusion/exclusion criteria, even down to specific start and stop events, varying dose levels and thousands of other variable criteria software can be used to speed up clinical trials.

    Sarah Beeby, continued: “As well as being an incredibly empowering project to be involved with it also enabled us to put CLiX through its paces and be even more confident in its ability. By using CLiX in the clinical trial setting we can offer significant de-risking for the program and potentially significant savings in development time by decreasing the total enrolment time, reducing protocol amendments, improving data robustness for the next development stage. As we all know time is a big factor with a significant number of trials failing to meet enrolment timelines.”

    Clinithink CEO, Chris Tackaberry said: “Sarah has huge experience in the life science industry and we are really excited that she has chosen to join Clinithink as the executive leading our life science business. We are confident we can make a real difference in this space and have already seen exciting traction since Sarah has joined us.”

     

     

     

    Clinithink’s CLiX natural language processing solution plays a key role in achieving a GUINNESS WORLD RECORDS™ title for fastest genetic diagnosis

    Clinithink has helped to achieve a GUINNESS WORLD RECORDS title for the Fastest genetic diagnosis. The project successfully compressed the time needed to diagnose rare genetic disorders in newborns through DNA sequencing to 19.5 hours, setting a new GUINNESS WORLD RECORDS title in a seamless end-to-end process and provided further evidence of its patented CLiX natural language processing (NLP) solution used in clinical trials.

    Clinithink participated in this exciting project with Rady Children’s Institute of Genomic Medicine (RCIGM), San Diego, California and its partners, including Alexion, Illumina, Edico Genome and Diploid.

    Clinithink’s patented CLiX natural language processing (NLP) solution was needed for two key activities in the process: quickly combing through electronic medical records to extract crucial phenotype information to then compare with over 12,000 phenotypes (plus an additional 15,000 synonyms) describing the characteristics of thousands of rare diseases. The solution can perform both of these tasks in seconds compared to the hours or days it would take a highly skilled specialist physician to do.

    Sarah Beeby SVP, Life Sciences said: “Not only did this exciting project prove the value of our technology, the humbling reality is that this work can help save the lives of children with rare diseases.”

    Narrative data is a valuable asset in healthcare but is largely inaccessible due to its lack of structure as existing technologies rely on structured data or key word searches. CLiX can ‘read’ thousands of clinical documents an hour and extract the information they contain. This has significant benefit, as shown with the Rady collaboration, in the clinical setting and is also very powerful for clinical trials as it can optimize the development process along the entire continuum – site selection, protocol optimization and enrolment. In simple terms our software can automate the bulk of pre-screening and site feasibility which is still undertaken manually. By targeting very specific patient inclusion/exclusion criteria, even down to specific start and stop events, key symptoms, medications and thousands of other variable criteria software can be used to speed up clinical trials.

    Sarah Beeby, continued: “As well as being an incredibly empowering project to be involved with it also enabled us to put CLiX through its paces and be even more confident in its ability. By using CLiX in the clinical trial setting we can offer significant de-risking for the program and potentially significant savings in development time by decreasing the total enrolment time, reducing protocol amendments, improving data robustness for the next development stage, etc. As we all know time is a big factor with a significant number of trials failing to meet enrolment timelines.”

    Clinithink CEO, Dr Chris Tackaberry said: “We are absolutely delighted that our patented CLiX natural language processing (NLP) solution played a key role in this success. Not only did this exciting project prove the value of our technology, the humbling reality is that this pioneering work can help save the lives of children with rare diseases. We are extremely proud of the contribution our solution can make to the care of those children.”

    A short video can be viewed for further information here.

     

    The full press release can be viewed here.

     

    http://www.clinithink.com

     

     

    Note to Editors:

    See further information from the Rady Children’s Institute for Genomic Medicine (RCIGM) led consortium at: https://www.rchsd.org/about-us/newsroom/press-releases/new-guinness-world-records-title-set-for-fastest-genetic-diagnosis/

     

    Clinithink plays a key role in achieving a GUINNESS WORLD RECORDS™ title for Fastest genetic diagnosis

    Clinithink has helped to achieve a GUINNESS WORLD RECORDS title for the Fastest genetic diagnosis. The project successfully compressed the time needed to diagnose rare genetic disorders in newborns through DNA sequencing to 19.5 hours, setting a new GUINNESS WORLD RECORDS title in a seamless end-to-end process.

    Clinithink participated in this exciting project with Rady Children’s Institute of Genomic Medicine (RCIGM), San Diego, California and its partners, including Alexion, Illumina, Edico Genome and Diploid.

    This is an astonishing achievement and makes a huge difference to the care of critically ill newborn children suffering from rare disease because of the huge potential to improve the outcome made possible by faster diagnosis.

    Clinithink’s patented CLiX natural language processing (NLP) solution was needed for two key activities in the process: quickly combing through electronic medical records to extract crucial phenotype information to then compare with over 12,000 phenotypes (plus an additional 15,000 synonyms) describing the characteristics of thousands of rare diseases. The solution can perform both of these tasks in seconds compared to the hours or days it would take a highly skilled specialist physician to do.

    Clinithink CEO, Dr Chris Tackaberry said: “We are absolutely delighted that our patented CLiX natural language processing (NLP) solution played a key role in this success. Not only did this exciting project prove the value of our technology, the humbling reality is that this pioneering work can help save the lives of children with rare diseases. We are extremely proud of the contribution our solution can make to the care of those children.”

    A short video can be viewed for further information here.

     

    The full press release can be viewed here.

     

    http://www.clinithink.com

     

     

     

    Note to Editors:

    See further information from the Rady Children’s Institute for Genomic Medicine (RCIGM) led consortium at: https://www.rchsd.org/about-us/newsroom/press-releases/new-guinness-world-records-title-set-for-fastest-genetic-diagnosis/

     

    Q & A with Clinithink’s Charles Legg

    Charles Legg is Vice President of Life Sciences for North America at Clinithink. Before Clinithink, he spent over two decades leading cross-functional clinical development teams at pharmaceutical and biotechnology companies. An experienced executive and entrepreneur, Charles’ motivation to come to Clinithink stems from his belief that the company’s AI software meets a critical unmet need: the necessity for a faster, more efficient way to match patients with clinical trials.

    Q: As a life science executive in clinical development, what were some of your primary challenges?

    A: As a senior executive involved in clinical development , the ultimate challenge was to find ways to increase speed to market and manage spend vs. risk along the way. This meant optimizing protocols, selecting the right sites, finding qualified patients and demonstrating statistical significance for our products. With electronic health record systems, researchers now have large patient datasets containing extraordinary amounts of information. The challenge is how to mine this data. It’s fair to say, the promise has not lived up to the hype. Until now.

    Q: What got you interested in Clinithink?
    A: I saw that Clinithink had put a lot of thought and rigor into creating and developing software that would disrupt the industry. The reason is they recognized most of the valuable information in electronic health data is in narrative free text, not structured data. Clinithink’s CLiX ENRICH can “read” thousands of clinical documents an hour and extract the information they contain. When I first saw CLiX ENRICH in action, it was apparent how powerful it was. Existing technologies rely on structured data or key word searches. These can be helpful, but aren’t game changing. The bulk of pre-screening and site feasibility work is still manual review. CLiX ENRICH largely automates this process and targets very specific patient inclusion/exclusion criteria, even down to specific start and stop events, varying dose levels and thousands of other variable criteria. Currently these can only be found through laborious manual search.

    Q: How does Clinithink save time and money during the clinical trial process?

    A: Our software speeds up clinical trials, optimizing the development process along the entire continuum – site selection, protocol optimization and enrollment. The net effect – significant de-risking for the program and potentially significant savings in development time by decreasing the total enrollment time, reducing protocol amendments, improving data robustness for the next development stage, etc. Time’s a big factor in a program’s cost and even more important for patients waiting for an important new therapy. E.g. a sponsor looking to identify and contract with sites will rely on site investigators and their teams to approximate the number of site patients, but this requires guesswork especially when complex inclusion/exclusion criteria are involved. It’s fairly common down the road that some of those patients don’t materialize. In fact, more than 80% of trials fail to meet enrollment timelines, and nearly 50% of sites enroll one or no patients. With CLiX ENRICH, you can identify in advance, sites with the greatest number of patients matching a trial’s criteria. Removing/reducing that level of uncertainty is a big deal.

    “Picking clinical sites can be a challenge. A variety of factors that must be considered, but certainly an important one is whether there are enough qualifying patients to justify opening a site. With CLiX ENRICH sponsors can identify sites with eligible patients before making a commitment.”

    Q: Will artificial intelligence replace KOLs?
    A: Absolutely not. KOLs and site investigators are the ones responsible and most qualified to determine which patients to recruit. However, investigators don’t have the time or manpower to manually review many thousands of pages of patient data every time it would be helpful. Clinithink automates 95% of this process, providing a powerful tool for investigators and freeing up precious time for site staff.

    Q: Any last thoughts to leave us with?
    A: I believe that the application of AI to clinical trials exemplifies a true technological breakthrough for the life science industry. There‘s an ongoing debate in the industry about how to improve the efficiency of innovation and drive down the average cost of clinical development. I think Clinithink are a piece of the solution which is why I’m so excited to have joined them.

    Clinithink to Showcase CLiX ENRICH at DIA 2017

    Automate and Accelerate Patient Recruitment with Clinithink at DIA 2017

    Visit booth 2448 at this years’ DIA Annual Meeting from June 18-22 in Chicago, IL and find out more about how Clinithink is creating a paradigm shift in patient enrollment for clinical trials. 

    Clinithink is exhibiting at DIA, the largest, longest-running event in the life sciences industry, to demonstrate how searching clinical narrative data in patient records markedly accelerates the rate at which patients are identified and enrolled into clinical trials.

    The exhibiting team invites DIA attendees from across the life sciences industry to visit booth 2448 to find out more about how Clinithink’s market-leading Artificial Intelligence (AI) technology is creating a paradigm shift in patient enrollment using existing, available, real-world data. Clinithink’s CLiX ENRICH solution largely automates the pre-screening process, drastically reducing the time and cost of this critical part of the clinical trial process. Using the solution, investigators at Mount Sinai and elsewhere have demonstrated a 10-fold increase in pre-screening yield and enrollment rate. CLiX ENRICH is effective for both common and rare disease clinical trials.

    On attending DIA 2017, Clinithink CEO, Dr Chris Tackaberry, said, “We are excited to be part of the most anticipated life sciences event of the year and demonstrate how using CLiX ENRICH is transforming the clinical trials landscape by accelerating patient enrollment, and offering data-driven insights into feasibility.”

    Now in its 53rd year, this years’ theme is: ‘Driving Insights to Action’ and will host 7,000 global healthcare professionals in the pharmaceutical, biotechnology, and medical device communities expected to attend from more than 51 countries. More information about DIA 2017 can be found here.

    Visit us at Booth 2448 and get the answers to your patient enrollment challenges! 

     

    Clinithink Named as a Top AI Company

    Health Data Management, a news website dedicated to delivering insightful analysis of technology trends, tools and strategies shaping healthcare’s future, has named Clinithink as one of the leading AI companies in healthcare.

    The two part article aims to highlight how the use of deep learning, machine learning and other AI approaches in healthcare is rapidly increasing. To demonstrate this, Health Data Management has published a list of leading e-health companies bringing a variety of approaches to the use of AI in the industry.

    In the article Health Data Management states that:

    “Clinithink’s intelligent data query platform gives healthcare and life sciences organizations the ability to extract value from unstructured data. Having recognized unstructured narrative as a rich source of information, CLiX ENRICH makes accessing this untapped resource possible to support analytics and decision making. Another platform, CLiX CNLP, was developed to enable interoperable access to and meaningful use of the volumes of existing unstructured, untapped clinical text typically locked inside electronic medical record systems and other clinical systems.”

    On being named by Health Data Management, CEO of Clinithink, Dr Chris Tackaberry, said: “We are delighted to be recognized for our contribution to healthcare transformation and look forward to helping many more organizations make use of valuable, existing unstructured health data to drive insights, improvements and data-driven healthcare.”

    The full article can be found here.

    About Clinithink

    Clinithink is the healthcare industry’s preferred text analytics provider, enabling innovative discoveries through the interrogation of unstructured data. CLiX ENRICH for Clinical Trials automates the process of reviewing narrative written by clinicians, as well as various documents and reports. This is achieved by designing CLiX Queries, within an intuitive user interface, which match study inclusion and exclusion criteria. The CLiX natural language processing (NLP) engine allows it to “read” and encode millions of documents against these queries, thus producing an ENRICHed List of highly eligible and priority patients who match the study criteria.

    For more information, visit http://www.clinithink.com or contact us at clinithink.com/contact/

    Mount Sinai presents on a paradigm shift in patient recruitment at SCOPE 2017

    Clinithink is hosting a luncheon presentation at SCOPE 2017 whereby Dr Steve Coca of Mount Sinai will present findings on using CLiX ENRICH for Clinical Trials to dramatically accelerate patient recruitment.

    New York, NY, 13 December 2016Clinithink, a market leading clinical trial patient recruitment solution provider, together with partners at the Icahn School of Medicine at Mount Sinai will demonstrate a marked improvement in the speed and quality of patient recruitment.  Using Clinithink’s Clinical Natural Language Processing (CNLP) technology to securely and accurately process unstructured patient data, investigative sites, like Mount Sinai, can now find 10X more patients matching clinical trial protocols in ¼  of the time it takes using current methods.

    Revolutionizing what is a largely manual review process, Dr. Steve Coca, Associate Professor of Medicine, Nephrology at Mount Sinai, will share two unique case studies in a presentation entitled, ‘A Breakthrough in Technology Enabled Clinical Trials Recruitment,’ on Day 2 of the SCOPE 2017 Summit.

    The 8th annual Summit for Clinical Ops Executives (SCOPE) will be held on January 24-26, 2017 in Miami, Florida. Renowned for providing valuable insight to members of the research community, SCOPE organizers are expecting 1,150 industry professionals and key thought leaders from over 500 organizations to gather and address critical issues facing the industry.

    Effective, timely patient recruitment and enrollment are well-known barriers to drug development but by automating the search for eligible patients using existing unstructured data Clinithink’s CLiX ENRICH for Clinical Trials is setting a new precedent in finding patients that meet inclusion and exclusion criteria quickly and seamlessly.

    Delegates to the Summit are invited to join Clinithink’s luncheon presentation on Wednesday the 25th of January at 12:10pm within the Patient Recruitment track in the ‘Recruitment in Resource-Constrained Environment: Traditional tactics, Analytics, Engagement’ session or contact info@clinithink.com to find out more.

    Clinithink’s new software version further enhances its capabilities to find eligible patients for clinical trials

    London, 07 December 2016 –  Clinithink has announced the latest  release of their Clinical Natural Language Processing (CNLP) solution, CLiX ENRICH 6.1, providing healthcare and life sciences organizations with enhanced capability to process and transform clinical narrative into actionable structured data which can be used to find patients matching clinical trial protocol criteria.

    Within clinical trials, the value of narrative data has been recognized as a primary resource for finding and recruiting eligible patients but it is still largely inaccessible due to its lack of structure. Clinithink’s CLiX ENRICH solution negates the need for time consuming manual review of patient charts and provides a flexible, scalable platform to process large volumes of narrative data before returning rich, structured information to query using clinical trial inclusion and exclusion criteria.

    The new version of CLiX ENRICH boasts enhanced features and capabilities all of which culminate to allow many different clinical trials and data analytics projects to be supported simultaneously from a single CLiX ENRICH environment. For Clinithink clients conducting several clinical trials simultaneously, CLiX ENRICH 6.1 can process all narrative data once and return customized output against each individual clinical trial protocol. Other important improvements in this release include:

    • Enhanced user experience – workflow tool can be used across the enterprise
    • Increased security and privacy capabilities
    • Improved processing speed and error handling
    • Scalability simplified with smaller infrastructure footprint
    • One click install
    • Built in options for document ingestion

    For the purposes of patient recruitment, sites can produce ranked lists of eligible patients to enroll against specific inclusion and exclusion criteria. This ‘ENRICHed List’ has been proven to dramatically reduce the time and investment currently required to identify and enroll patients for a variety of disease and medical device trials.  When commenting on the release of CLiX ENRICH 6.1, Clinithink VP Solutions, Paul Ellis said: “The release of CLiX ENRICH 6.1 further enhances Clinithink’s support for healthcare and life sciences organizations that are looking for a highly flexible, customizable and scalable platform for extracting maximum value from unstructured clinical narrative in pursuit of improved efficiency in meeting their target recruitment goals.”

    CLiX ENRICH Release 6.1 was recently released to customers. Interested parties who want to see how Clinithink’s CNLP solution extracts rich data from unstructured narrative are invited to register at https://clinithink.com/clix-notes/ or get in touch on info@clinithink.com .

    Clinithink Partners with Mount Sinai Health System to Transform Clinical Trials Recruitment

    Clinithink Partners with Mount Sinai Health System to Transform Clinical Trials Recruitment

    Mount Sinai Health System selects leading innovator in clinical trials natural language processing to enhance clinical trials operations

    New York, NY (June 21, 2016) – Following a successful evaluation of Clinithink, Ltd.’s CLiX ENRICH for Clinical Trials solution at the Icahn School of Medicine at Mount Sinai (ISMMS), Mount Sinai has signed an agreement with the company to deploy the solution across the organization to accelerate patient recruitment for clinical trials, as well as to support its personalized medicine initiatives.

    CLiX ENRICH will help to streamline the patient pre-screening process at Mount Sinai by processing large volumes of progress notes and reports from electronic health records and flagging patients whose clinical documentation indicates they closely match a trial’s inclusion/exclusion criteria. The result is an ENRICHed List, a prioritized shortlist of highly eligible patients. This will allow investigators to be much quicker in selecting patients to approach for consent and screening. The solution removes the need for extensive manual chart reviews almost entirely, releasing valuable time traditionally spent by site investigators and coordinators on this laborious task.

    A multidisciplinary team of investigators from The Samuel F. Bronfman Department of Medicine, The Charles Bronfman Institute of Personalized Medicine and the Division of Nephrology at The Mount Sinai Hospital, recently worked with an expert Clinithink team to apply CLiX ENRICH to an ongoing diabetic nephropathy trial and evaluate the results.

    “Using CLiX ENRICH, we did in a week what would have previously taken four months, so this could represent a paradigm shift in the way clinical trials are carried out for both common as well as rare diseases,” said Girish N. Nadkarni, MD, Clinical Instructor of Medicine/Nephrology at Mount Sinai and lead investigator for the CLiX ENRICH evaluation.

    Steven Coca, DO, Associate Professor of Medicine at Mount Sinai and executive sponsor of the evaluation added, “This technology allows us to speed up patient recruitment and find many more qualified candidates early in the process, allowing for shorter, more efficient trials and saving precious investigator and study coordinator time.”

    In a second case study, the evaluation team retrospectively applied CLiX ENRICH to a trial in a rare kidney disorder. The team found that CLiX ENRICH would have increased trial enrollment by 250 percent and eligible patients were found in a fraction of the time.

    “This technology is a game changer in the way we will find quality candidates for our clinical trials and will allow us to significantly increase the number of patients to whom we can offer participation in a clinical trial,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai.  “This initiative is perfectly aligned with Mount Sinai’s vision and mission to drive innovation in healthcare to benefit our patients.”

    “Clinical trial recruitment is becoming more and more difficult,” said Dr. Chris Tackaberry, MB, CEO of Clinithink.  “We believe that our CLiX ENRICH solution addresses this problem in a highly innovative and very significant way. We are delighted to be collaborating with Mount Sinai to demonstrate this and show that clinical narrative data, a currently untapped asset, can be successfully exploited with our technology in ways not previously possible.”

    DISCOVER CLiX ENRICH for Clinical Trials


    CLiX ENRICH CASE STUDY: MOUNT SINAI



    Prospective Trial in Patient Group with Diabetic Nephropathy

    CLiX ENRICH CASE STUDY: MOUNT SINAI



    Retrospective Trial in Patient Group with Rare Kidney Disease

    About the Mount Sinai Health System

    The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

    The System includes approximately 6,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is ranked as one of the nation’s top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2015-2016 “Best Hospitals” issue of U.S. News & World Report. Mount Sinai’s Kravis Children’s Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology, while Mount Sinai Beth Israel is ranked regionally.

    For more information, visit http://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

    About Clinithink

    Clinithink is the healthcare industry’s preferred text analytics provider, enabling innovative discoveries through the interrogation of unstructured data. CLiX ENRICH for Clinical Trials automates the process of reviewing narrative written by clinicians, as well as various documents and reports. This is achieved by designing CLiX Queries, within an intuitive user interface, which match study inclusion and exclusion criteria. The CLiX natural language processing (NLP) engine allows it to “read” and encode millions of documents against these queries, thus producing an ENRICHed List of highly eligible and priority patients who match the study criteria.

    For more information, visit http://www.clinithink.com or contact us at clinithink.com/contact/

    A Breakthrough in Clinical Trials Recruitment to be Presented at Clinical Trial Innovation Summit

    Steven Coca, MD will be presenting at the Cambridge Healthtech Institute’s annual Clinical Trial Innovation Summit (9-10 May 2016), illustrating the effectiveness of CLiX ENRICH in improving the speed and efficiency of the patient recruitment process.

    Dr. Coca will be referencing the results of two studies, one a retroactive analysis of a clinical trial for a rare disease and the other a live trial for diabetes with nephrology complications, to show how CLiX ENRICH can identify a larger cohort of high quality patients in a fraction of the time.

    Pharma Tech Outlook Selects Clinithink for Top 10 Clinical Data Management Solution Providers

    Fremont, CA—January 6, 2016—Pharma Tech Outlook (www.pharmatechoutlook.com) has chosen Clinithink, (www.clinithink.com) for its Top 10 Clinical Data Management Solution Providers 2015. The positioning is based on evaluation of Clinithink’s capabilities in extracting clinical information from unstructured narrative to accelerate the patient identification in the recruitment stage of clinical trials.

    The annual list of companies is selected by a panel of experts and members of Pharma Tech Outlook’s editorial board to recognize and promote technology entrepreneurship. “Clinithink has been making great strides in the Clinical Data Management arena. Their extensive experience and innovative solutions make them a frontrunner in this arena and we are happy to showcase them this year,” said Stacey Smith, Editor-in-Chief, Pharma Tech Outlook. “Clinithink’s solutions continue to break new ground, benefiting life sciences companies around the globe. We are excited to feature them in our Clinical Data Management edition this year.”

    “Clinithink is honored to be recognized by Pharma Tech Outlook’s panel of experts and thought leaders,” said Clinithink CEO, Dr Chris Tackaberry.  “Manual chart review to identify and recruit patients is expensive and time consuming but we’re offering a way to automate the review process that can significantly save time and money while enrolling patients against complex clinical inclusion and exclusion criteria.”

    About Clinithink

    With operations in the US and UK, Clinithink enables innovative discoveries for pharmaceutical companies, contract research organizations and providers delivering clinical trials through the interrogation of unstructured clinical narrative. By converting narrative into rich structured data, Clinithink’s technology enables analytics to help solve today’s toughest healthcare business problems. Through ease of integration, consumption and localization―Clinithink offers a smarter approach.

    For more information, visit http://www.clinithink.com or contact us at clinithink.com/contact/

    About Pharma Tech Outlook

    Pharma Tech Outlook is a vast portal for professionals to access information regarding the trends, opinions, and relevant discussions pertaining to challenges faced by the pharma landscape.

    The edition constantly endeavors to identify “The Best” in a variety of areas important to logistics arena. Through nominations and consultations with industry leaders, our editors choose the best in different domains. Clinical Data Management is a listing of Top 10 Clinical Data Management Solution Providers in the U.S.

    PenRad Demonstrates Power of Clinithink’s CLiX CNLP within vNext Solution for Radiology at RSNA

    Clinithink’s CLiX CNLP embedded for increased CDI precision in real time and clinical care guidelines

    Atlanta, Ga. (December 1, 2014) – Clinithink’s CLiX CNLP (Clinical Natural Language Processing) platform, embedded in the next generation vNext Solution with PenRad Technologies, the icon in radiology for Mammography Reporting and Information Systems (MIS), will be demonstrated at the Radiological Society of North America (RSNA) 2014 Annual Meeting in Booth 3100. By automating ICD-10-CM coding at the point of service in real-time and providing intelligent refinement prompts, CLiX CNLP enables increased accuracy in Clinical Documentation Improvement (CDI). Within PenRad’s vNext Solution, CLiX CNLP will also present evidence-based Appropriate Use Criteria (AUC) guidelines for diagnostic imaging, mandated to start in the U.S. January 2017. Read more

    Clinithink to showcase CNLP solution at EHI Live 2014

    Clinithink will be exhibiting at EHI Live 2014 on 4th and 5th November to discuss and demonstrate the clinical, efficiency and financial benefits of transforming clinical narrative into rich structured data.

    Based on stand A36 in NEC Hall 1, Birmingham, the Clinithink team will be available to explain how their CLiX CNLP (clinical natural language processing) solutioncan support clinicians with difficult-to-access, valuable patient data from their unstructured narrative. By unlocking unstructured clinical data from reports, discharge summaries, letters and notes in EPRs, Clinithink can arm healthcare professionals with actionable, structured patient information for more effective, faster clinical decisions at the point of care. Read more

    PenRad partners with Clinithink to optimize ICD-10 coding compliance at the point of dictation

    Clinithink’s technology to streamline efficiency of PenRad Mammography Information Systems radiology reporting

    Atlanta, Ga. (September 16, 2014) – PenRad Technologies Inc., the market leader in Mammography Information Systems (MIS) today announced its partnership with Clinithink to refine the process of clinical documentation for radiologists in real-time. PenRad is embedding Clinithink’s CLiX CNLP (Clinical Natural Language Processing) platform into its MIS solution to increase productivity, accuracy and efficiency of the mammography reporting workflow for its existing install base. Read more

    Clinithink debuts CLiX ENRICH platform, raises capital from existing investors to fuel growth

    New data abstraction capabilities designed to enable clinical analysis

    June 30, 2014 – London, UK  – Clinithink, an industry leading provider of technology to manage unstructured healthcare data, today announced its new data abstraction platform, CLiX ENRICH, and a further multi-million dollar equity finance deal with its existing institutional investors: New York based Vanguard Atlantic Ltd. and UK-based Finance Wales.

    There is evidence of significant traction for solutions in the healthcare analytics space that deal with unstructured data. A wide variety of healthcare companies are recognizing that considerable value lies within narrative clinical data, a previously untapped asset. Read more

    Farr Institute at Swansea University deploys CLiX to improve clinical analytics for population health

    Centre for Improvement in Population Health through E-records Research (CIPHER) accesses unstructured data with Clinithink’s Clinical Natural Language Processing (CNLP) CLiX technology for easy and rapid deployment.

    London, UK. (May 29, 2014) – Named after William Farr, a pioneer of the science of epidemiology, the Farr Institute’s Centre for Improvement in Population Health through E-records Research (CIPHER) group at Swansea University has deployed Clinithink’s CLiX technology as part of a novel “Appliance” solution to support the analysis of e-health record information linked to other routinely collected clinical data. Read more

    Mount Sinai’s Charles Bronfman Institute for Personalized Medicine uses CLiX for CNLP to support clinical decisions

    May 8th, 2014, Atlanta, Ga. – The Charles Bronfman Institute for Personalized Medicine (IPM) at the Icahn School of Medicine at Mount Sinai has deployed Clinithink’s CLiX technology to support the practice and development of personalized medicine. CLiX forms part of a solution that enables patients at Mount Sinai to receive more targeted, personalized care in real-time based on their own DNA.

    IPM has worked with Clinithink to integrate CLiX into the technology platform that underpins the Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomics (CLIPMERGE) Program at Mount Sinai. CLiX provides Clinical Natural Language Processing (CNLP) to support real-time “electronic phenotyping” being pioneered at IPM by identifying potentially relevant clinical attributes from rich narrative data stored within Mount Sinai’s Electronic Medical Record (EMR) and passing them to the CLIPMERGE decision support engine. Read more

    Clinithink Launches First Online Healthcare Solutions to Access and Activate Untapped Clinical Data

    March 19, 2014 – Clinithink, the world-leader in Clinical Natural Language Processing (CNLP) technology, launched its suite of CLiX ONLINE Solutions to translate unstructured clinical narrative. CLiX NOTES, CLiX PLUS and CLiX PRO—built on Clinithink’s unique CNLP technology platform—are the world’s first interactive, online solutions to structure and encode unstructured clinical narrative for the healthcare industry. Read more

    Clinithink Honored with Mediwales 2013 Innovation Judges’ Award

    11 December 2013, Bridgend, UK – Clinithink, a world-leader in clinical natural language processing (CNLP) technology, today announced that it received the 2013 MediWales Innovation Judges’ Award.

    The Judges’ Award recognizes the development of innovative technology and outstanding contribution to the Life Science Sector. Clinithink received this award for the significant success they have achieved in the US healthcare marketplace with their innovative CLiX technology. Read more

    Bringing Healthcare Data to Light

    Alpharetta, GA March 18, 2013- Clinithink releases an online version of their clinical natural language processing technology, CLiX.

    Clinithink has announced the release of an online version of CLiX, their clinical natural language processing (CNLP) engine. CLiX intelligently structures clinical narrative created by physicians and stored as free text in medical records; thereby making it possible to index, map and tag this data into a structured format to result in actionable information.

    CLiX Online is the first technology of its kind to be made available to the healthcare industry as an interactive service to structure and encode unstructured clinical narrative. The service will initially be offered as a free trial before moving to a subscription service in mid-2013. Read more

    Peter Neupert Joins the Board at Clinithink

    London, UK, 01 March 2013 – Peter Neupert , former Corporate Vice President of Microsoft Health Solutions Group and co-founder of MSNBC, has joined the Board at Clinithink, a healthcare technology company operating in the US and UK. Neupert’s appointment to the Board will take effect in February 2013.

    Currently an Operating Partner at Health Evolution Partners, a leading investment firm in the healthcare sector, Neupert’s extensive career as a world-class health technology innovator began when he founded drugstore.com in 1998. As one of the first to recognize the potential of B2C e-commerce platforms, drugstore.com went on to become a top online retail store and information site for health and wellness under Neupert’s leadership. Read more

    Command Health Chooses CLiX for Clinical NLP

    Atlanta, US 28 February  2013 – Command Health, an industry leader in medical documentation, will  leverage Clinithink’s CLiX solution as part of its software suite that enables its customers to improve the integrity and utility of the clinical data exchange between their Providers and their EMR technology.

    Command Health has been supplying the healthcare industry with software solutions to improve healthcare documentation for over 12 years with the goal of making the data entry process for Physicians more efficient and increasing the clinical value of the output produced. Read more

    ICA Selects Health Language to Strengthen Analytics and Reporting across Patient Populations

    DENVER, CO (February 14, 2013) — Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that ICA has selected Health Language® to support its health information exchange (HIE) platform. Health Language medical terminology management software and services will enable ICA, a leading provider of interoperability technology that enables care management and HIE, to create longitudinal patient records and enhance reporting and analytics across entire populations.

    ICA’s interoperability platform connects providers across the continuum of care through a series of modules that support clinical communications and information exchange. The company is preparing to launch an informatics module, CareAlign Insight, which houses a central data repository. Health Language helps support this initiative by providing a dual-engine that, in collaboration with Clinithink, transforms both free text and disparate data into standardized terminologies. Read more

    Welsh First Minister Opens Clinithink’s Development Center

    23 NOVEMBER 2012, BRIDGEND, WALES – Rt. Hon Carwyn Jones AM, First Minister of Wales, opens Clinithink’s global R&D center in Bridgend, emphasizing the Welsh government’s commitment to stimulating economic growth by attracting leading companies in the technology sector to Wales.

    Clinithink is a specialist technology supplier that produces innovative IT solutions for the healthcare market. The company has developed a state-of-the-art, cloud-based text processing capability that can be used to support data analytics, coding and decision-support in healthcare applications. This in turn helps providers of healthcare to improve care whilst at the same time operate more efficiently. Read more

    Clinithink Closes Investment Deal and Opens Doors for Healthcare

    26 July 2012, UK – Spurred on by policy reforms in the US, investment in health IT continues to surge in 2012 [external content no longer available] as more and more healthcare providers continue to implement technology to improve patient care and reduce the cost of delivering medical services. Demonstrating the trend to invest in high-value health IT solutions is Clinithink, a UK-based healthcare software company which has successfully concluded a Series A funding round led by Vanguard Atlantic, a US-based equity firm focused on technology.

    After securing an initial multi-million dollar investment during the 1st tranche of the company’s Series A funding round in March 2012, Clinithink secured additional multi-million dollar investments from Finance Wales, one of the UK’s largest regional SME investment companies, and existing investors to complete the round. The investment in Clinithink will fund ongoing development of the company’s technology, establish the company’s US operation, as well as its UK-based R&D function. Read more

    Healthcare IT Startup with Big Answers to Big Data

    April, 2012 – While US and European governments actively seek to reduce healthcare costs and improve outcomes, one UK-based startup is poised to answer the million dollar data analytics question: how can we make meaningful use of data if we don’t know what it means?

    Clinithink has developed an innovative cloud-based data analytics technology specifically for healthcare applications. Clinithink’s patent-pending Clinical Language Indexing software (CLiX) uses Natural Language Processing and propriety algorithms to construct fully-coded output from physicians’ notes using industry data standards (ICD-9, ICD-10, and SNOMED CT). Read more

    HLI and Clinithink Showcase Language Processing Tool at HIMSS

    DENVER – February 16, 2012 – Health Language, Inc. (HLI), the global leader in medical terminology management, today announced a proof-of-concept collaboration project with Clinithink, Ltd, a natural language processing specialist organization.

    The dual-engine tool identifies critical patient data found in provider notes and maps the free-text to standardized code sets, allowing physicians to maintain their standards of practice while accurately integrating patient data into healthcare systems. The solution will be showcased at HLI booth 466 during exhibit hours at HIMSS 2012. Read more

    Acusis and Clinithink Collaborate to Enrich Clinical Documentation

    29 September 2011, Pittsburgh, PA, USA and London, UK – Acusis, LLC and Clinithink Ltd. have agreed to collaborate with the initial goal of enhancing the clinical documentation process in ambulatory and acute care settings through the integration of Clinithink’s new and transformative technology into the market-leading Acusis solution: AcuSuite®.

    The collaboration serves to create an integrated solution which identifies and analyzes trends in rich narrative clinical data to enable improved outcomes.This endeavor is in line with both companies shared vision to support healthcare organizations in their quest to improve care decisions through knowledge derived from data. Read more